# Ph II CHOP+Velcade in Mediastinal LBCL

> **NCT00361621** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 3 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** bortezomib
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone
- **RADIATION:** Radiation therapy

## Key facts

- **NCT ID:** NCT00361621
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-07
- **Primary completion:** 2007-11
- **Final completion:** 2008-05
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Closed due to slow accrual
- **Last updated:** 2012-12-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00361621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00361621, "Ph II CHOP+Velcade in Mediastinal LBCL". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00361621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*